Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
ConclusionsUpadacitinib 15 mg and adalimumab had similar safety profiles with the exception of HZ and OIs, consistent with what was observed in rheumatoid arthritis. Rates of malignancies, MACEs, VTEs, and deaths were comparable among patients receiving upadacitinib and adalimumab. No new safety risks emerged with longer-te rm exposure to upadacitinib.Trial Registration NumbersSELECT-PsA 1: NCT03104400; SELECT-PsA 2: NCT03104374.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Anemia | Arthritis | Cancer & Oncology | Cardiology | Cardiovascular | Common Cold | Heart | Herpes | Humira | Laboratory Medicine | Psoriatic Arthritis | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | Tuberculosis